IEFM
ZYNE

IQ EQ Fund Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

IQ EQ Fund Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-122,892
Closed -$65.1K – 249
2022
Q4 		$65.1K Buy
122,892
+6,112
+5% +$3.88K 0.01% 226
2022
Q3 		$85K Sell
116,780
-107,441
-48% -$122K 0.02% 206
2022
Q2 		$256K Buy
224,221
+10,752
+5% +$13.7K 0.05% 172
2022
Q1 		$438K Buy
213,469
+9,960
+5% +$23.7K 0.07% 165
2021
Q4 		$586K Buy
203,509
+18,574
+10% +$68.7K 0.09% 167
2021
Q3 		$784K Sell
184,935
-777,697
-81% -$3.47M 0.12% 162
2021
Q2 		$5.09M Buy
962,632
+241,045
+33% +$1.16M 0.78% 37
2021
Q1 		$3.35M Buy
721,587
+649,418
+900% +$2.94M 0.59% 51
2020
Q4 		$238K Buy
72,169
+40,617
+129% +$154K 0.06% 214
2020
Q3 		$104K Buy
31,552
+19,266
+157% +$70.8K 0.03% 191
2020
Q2 		$41K Buy
+12,286
New +$58.1K 0.01% 187

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IQ EQ Fund Management's ZYNE Position: Q1 2023 in Review

IQ EQ Fund Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 122,892 shares — an estimated $65.1K sold.

IQ EQ Fund Management first reported a position in ZYNE in Q2 2020 and held it in 11 quarters. The position peaked at $5.09M in Q2 2021. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • IQ EQ Fund Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • IQ EQ Fund Management sold 122,892 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $65.1K.
  • IQ EQ Fund Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2020 and held it in 11 quarters.
  • IQ EQ Fund Management's Zynerba Pharmaceuticals, Inc position peaked at $5.09M in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on IQ EQ Fund Management's 13F filing for Q1 2023, filed 10 May 2023.